Leukemia Inhibitory Factor: An Important Cytokine in Pathologies and Cancer

• Published in: Biomolecules (Basel, Switzerland) Vol. 12; no. 2; p. 217
• Main Authors: Jorgensen, Megan M, de la Puente, Pilar
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 27-01-2022; MDPI
• Subjects: Binding sites; Breast cancer; Cancer; cancer progression; Cell differentiation; Cell growth; Chemoresistance; Cytokines; Epigenetics; Fibroblasts; Gene expression; Humans; IL-6 cytokine family; Interleukin 6; Kinases; Leukemia; Leukemia inhibitory factor; Leukemia Inhibitory Factor (LIF); Leukemia Inhibitory Factor - metabolism; LIFR; Localization; Malignancy; Metastases; Myeloid leukemia; Neoplasms; Patients; Physiology; Review; Signal Transduction; Solid tumors; Stem cells; Leukemia Inhibitory Factor (LIF); IL-6 cytokine family; chemoresistance; LIFR; cancer; cancer progression
• ISSN: 2218-273X; 2218-273X
• DOI: 10.3390/biom12020217

Leukemia Inhibitory Factor (LIF) is a member of the IL-6 cytokine family and is expressed in almost every tissue type within the body. Although LIF was named for its ability to induce differentiation of myeloid leukemia cells, studies of LIF in additional diseases and solid tumor types have shown that it has the potential to contribute to many other pathologies. Exploring the roles of LIF in normal physiology and non-cancer pathologies can give important insights into how it may be dysregulated within cancers, and the possible effects of this dysregulation. Within various cancer types, LIF expression has been linked to hallmarks of cancer, such as proliferation, metastasis, and chemoresistance, as well as overall patient survival. The mechanisms behind these effects of LIF are not well understood and can differ between different tissue types. In fact, research has shown that while LIF may promote malignancy progression in some solid tumors, it can have anti-neoplastic effects in others. This review will summarize current knowledge of how LIF expression impacts cellular function and dysfunction to help reveal new adjuvant treatment options for cancer patients, while also revealing potential adverse effects of treatments targeting LIF signaling.